# Oral azacitidine PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/oral-azacitidine

> The next catalyst for oral azacitidine, sponsored by BRISTOL MYERS SQUIBB CO (BMY), is its topline data readout, Jul to Oct 2028.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | oral azacitidine |
| Codes | BMS-986345 |
| Sponsor | BRISTOL MYERS SQUIBB CO (BMY) https://sec-api.dev/companies/bmy/catalysts |
| Indications | [Myelodysplastic Syndromes](https://sec-api.dev/indications/myelodysplastic-syndromes) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Jul to Oct 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2/3. Indication: Myelodysplastic Syndromes.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05469737 (A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-07-31 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT05469737

### July 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2/3. Indication: Myelodysplastic Syndromes.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05469737 (A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-07-31 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT05469737

## Same indication

- [Decitabine](https://sec-api.dev/pdufa/decitabine) (NVS)
- [Elritercept](https://sec-api.dev/pdufa/elritercept) (TAK)
- [Luspatercept](https://sec-api.dev/pdufa/luspatercept) (BMY)
- [OJJAARA (momelotinib)](https://sec-api.dev/pdufa/momelotinib) (GSK)
- [Evrenzo® (roxadustat)](https://sec-api.dev/pdufa/roxadustat) (KYNB)
- [Tebapivat](https://sec-api.dev/pdufa/tebapivat) (AGIO)

Calendar months: [July 2028](https://sec-api.dev/fda-calendar/2028-07)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/oral-azacitidine.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Oral azacitidine PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/oral-azacitidine

```bibtex
@misc{secapidev_pdufa_oral_azacitidine_20261116,
  title        = {Oral azacitidine PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/oral-azacitidine}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_oral_azacitidine_20261116","title":"Oral azacitidine PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/oral-azacitidine","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
